Literature DB >> 31982626

Statin use and risk of tuberculosis: a systemic review of observational studies.

Haizhen Duan1, Tongying Liu2, Xiaojun Zhang2, Anyong Yu2, Yu Cao3.   

Abstract

OBJECTIVES: Statin intake may be linked with a lower risk of several infectious diseases, including tuberculosis, which is an important cause of mortality worldwide. The aim of this study was to investigate the definite impacts of statins on the risk of tuberculosis (TB) in diabetic patients and in the general population.
METHODS: Four databases were thoroughly searched from inception up to July 2019. Articles in any language were included if they assessed and clarified statin intake, presented the risk of TB in diabetes mellitus (DM) patients or the general population, and reported odds ratios (ORs), relative risks (RRs), or hazard ratios (HRs) or contained data for relevant calculation. RRs with 95% confidence intervals (CIs) were pooled using random-effects models regardless of heterogeneity quantified by Cochran's Q and I2 statistics.
RESULTS: Six articles reporting observational studies involving 2 073 968 patients were included. Four reported cohort studies, one a nested case-control study, and one was an abstract. Statin use significantly reduced the risk of TB in DM patients by 22% (pooled RR 0.78, 95% CI 0.63-0.95), with severe heterogeneity (I2 = 76.1%). Statin intake also significantly decreased the risk of TB in the general population by 40% (pooled RR 0.60, 95% CI 0.50-0.71), with severe heterogeneity (I2 = 57.7%).
CONCLUSIONS: Statin use is related to a considerably lower risk of TB in both DM patients and the general population. However, these conclusions should be interpreted with caution given the possible remaining confounding, and call for large-size and multicenter randomized controlled studies in the future.
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Diabetes mellitus; Risk; Statins; Systemic review; Tuberculosis

Mesh:

Substances:

Year:  2020        PMID: 31982626     DOI: 10.1016/j.ijid.2020.01.036

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  6 in total

Review 1.  Further insights into to the role of statins against active tuberculosis: systematic review and meta-analysis.

Authors:  Edinson Dante Meregildo-Rodriguez; Eleodoro Vladimir Chunga-Chévez; Robles-Arce Luis Gianmarco; Gustavo Adolfo Vásquez-Tirado
Journal:  Infez Med       Date:  2022-06-01

2.  Reply to Lai et al.

Authors:  Vignesh Chidambaram; Petros C Karakousis
Journal:  J Infect Dis       Date:  2021-10-13       Impact factor: 7.759

Review 3.  Host Immune-Metabolic Adaptations Upon Mycobacterial Infections and Associated Co-Morbidities.

Authors:  Alba Llibre; Martin Dedicoat; Julie G Burel; Caroline Demangel; Matthew K O'Shea; Claudio Mauro
Journal:  Front Immunol       Date:  2021-09-23       Impact factor: 7.561

Review 4.  Diabetes-Associated Susceptibility to Tuberculosis: Contribution of Hyperglycemia vs. Dyslipidemia.

Authors:  Minh Dao Ngo; Stacey Bartlett; Katharina Ronacher
Journal:  Microorganisms       Date:  2021-11-02

5.  Are There Sex-Specific Differences in Response to Adjunctive Host-Directed Therapies for Tuberculosis?

Authors:  Noton K Dutta; Bianca E Schneider
Journal:  Front Immunol       Date:  2020-07-07       Impact factor: 7.561

6.  The association of atherosclerotic cardiovascular disease and statin use with inflammation and treatment outcomes in tuberculosis.

Authors:  Vignesh Chidambaram; Jennie Ruelas Castillo; Amudha Kumar; Justin Wei; Siqing Wang; Marie Gilbert Majella; Akshay Gupte; Jann-Yuan Wang; Petros C Karakousis
Journal:  Sci Rep       Date:  2021-07-27       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.